Introduction
============

*Helicobacter pylori* (*H. pylori*) is a bacterium that induces chronic gastric inflammation and is the most important cause of peptic ulcer worldwide. Bacterial colonization mostly remains active lifelong if an effective therapy is not applied. *H. pylori* has been demonstrated to be susceptible to some common antibiotics *in vitro*, therefore, a successful eradication should not be difficult. However, recently, *H. pylori* infection has become difficult to treat. The failure of the therapy is mainly due to the presence of antibiotic-resistant organisms. Despite the fact that there is a general agreement that the main reason for eradication failure is the rapid increase in bacterial antibiotic resistance, poor patient compliance and rapid metabolism of conventional PPIs might also be crucial elements of this relevant problem, which could have not been properly considered in this setting.

What Has Been Done to Solve This Problem?
=========================================

International guidelines ([Table 1](#T1){ref-type="table"}) discouraged clarithromycin and levofloxacin use in areas with resistance rates higher than 15% ([@B2]; [@B21], [@B17]; [@B13]; [@B15]; [@B33]; [@B38]; [@B3]). However, it is known that guidelines are concentrated on the clinical practice in the context of empirical settings. Consequently, first line schedules with expected high eradication levels, i.e., bismuth containing quadruple therapy or non-bismuth concomitant quadruple therapy, are suggested ([@B38]). However, the 2009 Asia-Pacific guidelines highlighted a similar efficacy for both 14-day triple therapy and bismuth containing quadruple in first line ([@B4]). We here emphasize that quadruple therapies require daily assumption of an excessive number of tablets (14 and 8 for bismuth and non-bismuth containing schedules, respectively) ([@B14]). Therefore, an evident doubt should be raised about the compliance. A complete adherence may be expected by subjects who are persuaded by major conditions, such as MALT lymphoma, family history of gastric cancer or peptic ulcer, particularly when complicated by episodes of bleeding, and the need for a long-term assumption of drugs able to induce gastric lesions, such as non-steroidal anti-inflammatory ones. Conversely, the majority of *H. pylori* positive subjects are dyspeptic or asymptomatic and could not be driven by convincing motivations, since the eradication of the bacterium is often not accompanied by a clinical benefit ([@B39]). An incomplete adherence to an antibiotic therapy may be an important reason of resistance onset, since it stimulates resistant mutant development ([@B25]). Moreover, bismuth containing quadruple therapy includes the use of tetracycline, which shows a very low resistance in Europe (1--5%) ([@B11]). Nonetheless, in Asia, even tetracycline resistance rates of 19% have been reported ([@B8]). So, in the near future an increase of resistance to this antibiotic could be consequent to its use on a large scale with an incomplete patient adherence ([@B9]). Additionally, metronidazole resistance is generally estimated to be no lower than 50% in Asia. Concomitant therapy implies the use of three conventional antibiotics with the evident aim to overcome the resistance to each single drug due to the overall combined effect of the regimen. Presumably, for this reason, concomitant schedule is suggested as the treatment of choice, when compared to sequential therapy ([@B16]). A final point concerns the duration of suggested first line therapies. The commercial kit of bismuth containing quadruple therapy provides a number of pills necessary for a 10-day schedule and the same period is the minimal time requested for concomitant regimen. Nevertheless, a prolongation to 14 days of both treatments seems to improve their effectiveness ([@B3]; [@B17]). Interestingly, in a recent systematic review and meta-analysis [@B5] showed that high-dose PPI-amoxicillin dual therapy is comparable to recommended rescue therapies for *H. pylori* infection. On these bases, the possibility of improving *H. pylori* treatment outcome with new PPIs able to increase the effectiveness of antibiotics in gastric microniche should open a new scenario. This action could be a rescue solution in order to help clinicians to restart the war against gastric cancer and other *H. pylori*-related diseases.

###### 
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Proton Pump Inhibitors in Eradication Regimens of *H. pylori*
=============================================================

Proton pump inhibitors (PPIs) are commonly used in all therapeutic lines for eradication of *H. pylori*. There is no empiric anti-*H. pylori* therapeutic regimen able to eradicate 100% of infections and, therefore, researchers constantly attempt to find better formulations. At the time of the first eradication attempts, PPI-based therapy was found to show a higher efficacy in comparison with non-PPI-based therapy. Therefore, the prescription of anti-secretory drugs is considered necessary for the efficacy of antibiotic therapy. The entire impact of this procedure is due to the following reasons. First, induced hypochloridria is a phenomenon which indirectly influences successful colonization of *H. pylori* in gastric territory, thus the bactericidal effects of available antibiotics can be easily observed ([@B24]). Additionally, current evidence insists on the role of hypochloridria for enforcing the deadly effect on the bacterium colonization in the stomach. Moreover, the addition of lansoprazole (as major conventional antisecretory drug) in culture media reduces the survival rate of the *H. pylori*. Hypothetically, this event can happen also in the gastric mucosa ([@B10]). Therefore, it can be asserted that increasing the concentration of lansoprazole drastically reduces the *H. pylori* survival at normal acidity. Moreover, there are some reports showing that, at least for amoxicillin, the minimal inhibitory concentration (MIC) is increased in relation to a high pH following the presence of antisecretory drug. Analogously, increasing pH can highly improve the bactericidal effects of clarithromycin in gastric juice. On the other hand, long term use of conventional PPIs may induce or worsen atrophic gastritis in patients colonized with *H. pylori* ([@B10]; [@B30]). Therefore, long-term use of PPIs in *H. pylori* positive patients is discouraged. In this context, we believe that the availability of vonoprazan as an alternative to PPIs is relevant in empiric therapy against *H. pylori* infection.

Vonoprazan Advantages Compared to Other PPIs
============================================

There are some speculative arguments in favor of the application of vonoprazan instead of other PPIs as antisecretory drugs: (1) it is more potent in the inhibition of acid secretion, (2) it has a fast onset of action, (3) less antisecretory variation is reported, as well as (4) greater safety, and (5) better tolerability. In brief, pharmacodynamic characteristics of vonoprazan clearly suggest a better performance when compared to conventional PPIs. In [Figure 1](#F1){ref-type="fig"}, eradication rates following the application of vonoprazan versus conventional PPIs in triple therapy regimens against *H. pylori* are reported. In three retrospective studies carried out between 2013 and 2015 ([@B37]; [@B35]), the efficacies of vonoprazan 20 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid for a period of 7 days were examined. ^13^C-urea breath test, as recommended by current guidelines, was the confirmation test in those studies. In the only available randomized clinical trial by [@B26] vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 or 400 mg bid were used for 7 days. Similar to other studies, UBT was applied to confirm the successful eradication of *H. pylori* infection. The results of these studies are summarized in [Figure 1](#F1){ref-type="fig"}. The results of these studies and the related meta-analysis report a very interesting and surprising finding: the possibility that an old therapeutic regimen, which all current guidelines suggest should be removed from the clinical practice because it is outdated and ineffective, can be effective again when combined with a new modality of acid-inhibition.

![Different eradication rates observed following application of vonoprazan versus conventional PPIs.](fphar-10-00316-g001){#F1}

Discussion
==========

Until 2014, most of the trials were devoted to designing better therapies for *H. Pylori* infection by using various antibiotics in formulation of triple or quadruple therapies; however, some reports focused the attention on a possible relevant role of PPIs in eradicating regimens ([@B34]). With this regard, a pioneering strategy has been initiated in Japan by the advent of a new PPI, i.e., vonoprazan ([@B34]). The sharp decrease in eradication rates of therapies using conventional PPI was the main rationale for introducing vonoprazan in the clinical practice ([@B1]). As a whole, the actual value of conventional PPIs being debated for the following reasons: (i) slow onset of pharmacological action in acidic gastric microniche, (ii) instability in acidic condition of human stomach and (iii) problematic variations observed in genetic polymorphisms of cytochrome P450 (CYP) 2C19 metabolism. Additionally, recent evidence demonstrates that high-dose PPI-amoxicillin dual therapy is comparable to recommended rescue therapies ([@B36]). Presumably, the set of all these problems stimulated the researchers to develop the new generation of PPI called "Vonoprazan fumarate" (Takecab^TM^). Since 2015, it has become a first-in-class potassium-competitive acid blocker in Japan ([@B6]). Vonoprazan shows a bioactivity 300 times greater when compared with lansoprazole ([@B6]; [@B1]; [@B7]; [@B23]). Similar to PPIs, vonoprazan reduces gastric hydrogen/potassium acid-inhibitory effects even if it shows a higher stability in gastric harsh conditions. This property may explain its effects in improving the efficacy rate of conventional triple therapy for *H. pylori* infection. *H. pylori* therapy was covered by the Japanese insurance system, thus more patients were admitted to receive therapy including vonoprazan in this country with the possibility of performing clinical studies regarding its efficacy. Recently, [@B29] showed the effectiveness of vonoprazan-based *H. pylori* eradication therapy among Japanese populations; they found Vonoprazan-based therapy to be more effective than conventional PPI-based therapy, at least in clinical settings. Moreover, [@B31] reported that the eradication rate of first-line therapy using vonoprazan-based amoxicillin and clarithromycin in a week is superior to conventional PPI-based therapy. The problem with this study was that the eradication rate was around 90%. The promising point in their study was the well-tolerated rate of vonoprazan-based therapy in patients. Recently, [@B28] have shown that the dual therapy using vonoprazan and amoxicillin can brings a higher eradication rate than standard *H. pylori* treatment. With this regard, in a Randomized Control Trial, [@B27] concluded that vonoprazan is the future of successful therapy of *H. pylori* in different regions. Again, this research group confirmed that there is no adverse side effect due to the application of vonoprazan in therapeutic regimens of *H. pylori*. In order to examine the effect of vonoprazan in third-line therapy, [@B32] have shown that a 7-day triple therapy containing vonoprazan, amoxicillin, and sitafloxacin brings higher efficacy rate when compared with a combined regimen with PPI, sitafloxacin and amoxicillin. To the date of writing this paper (February 2019), there are no other published trials examining the efficacy of vonoprazan in *H. pylori* infected populations in countries other than Japan. So far, many PPIs have been investigated in clinical trials, but the newly introduced acid inhibitor vonoprazan brought a glimpse of hope to have a higher efficacy in treating the *H. pylori* infection. In a meta-analysis by [@B12] authors showed many benefits of the vonoprazan-based triple therapy in comparison with the same regimen including conventional PPIs. However, this analysis included retrospective observational studies thus raising a serious problem about the real suitability of this meta-analysis. Nevertheless, the finding could support speculative considerations, i. e. switching to vonoprazan as novel acid blocker can initiate a new era for of *H. pylori* treatment with an unexpected reassessment of triple therapy, at least in regions with low rate of clarithromycin resistance ([@B23]). Therefore, a prospective study using vonoprazan in other regions is needed in order to generalize the suggestion of promoting vonoprazan as the most useful anti-acid in the combination of antibiotics against *H. pylori* thus avoiding that a limited geographic phenomenon can become a confusing paradigm to be applied worldwide.

Future Perspective
==================

After two decades, it seems that the era of conventional PPI may be ending and the one of vonoprazan is beginning in order to obtain a better therapy for *H. pylori* infection. Nevertheless, the newly proposed regimen including vonoprazan should be evaluated in countries different from Japan in order to consider it as a global drug. In conclusion, based on the increased antibiotic resistance rates, the scarceness of hope for the arrival of new antibiotics and the poor enthusiasm of companies funding the development of an efficient vaccine, vonoprazan-based regimens may have disclosed an excellent option to test. The lack of knowledge concerning the effectiveness of vonoprazan in other therapeutic regimens is a gap which could be filled by future studies ([@B12]). Furthermore, the actual effectiveness of vonoprazan in regions with high rate of clarithromycin resistance (more than 20%) is not clear yet; this is another crucial point. Nevertheless, according to current knowledge, strategies which aim to maintain a high gastric pH may overcome the problem of antibiotic resistance hampering a successful *H. pylori* therapy. This solution may be translated in vonoprazan. Conclusively, switching to using vonoprazan as novel acid blocker may be a stimulating topic for the near future since it could disclose a new scenario in *H. pylori* treatment.
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